The global veterinary regenerative medicine market size was valued at USD 1.49 billion in 2025 and is projected to grow from USD 1.64 billion in 2026 to USD 3.49 billion by 2034, registering a CAGR of 9.91% during the forecast period (2026–2034). North America dominated the veterinary regenerative medicine market with a market share of 37.29% in 2025.
Veterinary regenerative medicine comprises advanced biological therapies that stimulate the repair, regeneration, and restoration of damaged tissues and organs in animals. These therapies include stem cell therapy, platelet-rich plasma, and other treatments for orthopedic disorders, tendon and ligament injuries, osteoarthritis, and wound healing. They are increasingly used in companion animals and livestock management to improve recovery, reduce pain, and enhance mobility.
The veterinary regenerative medicine market demand is increasing due to rising pet ownership, growing animal healthcare spending, and expanding adoption of advanced veterinary therapies. Increasing research investments, technological advancements, and supportive veterinary infrastructure are further contributing to veterinary regenerative medicine market growth.
Download a Free Sample To learn more about this report,
The veterinary regenerative medicine market is moderately exposed to supply chain disruptions due to its reliance on specialized biological materials, laboratory reagents, cryopreservation systems, and temperature-controlled logistics. Interruptions in the global supply of cell culture media, stem cell processing materials, and advanced laboratory equipment can delay therapy development, manufacturing, and clinical availability across veterinary healthcare facilities. Cross-border transportation constraints and shortages of specialized consumables also increase operational costs and extend product delivery timelines, influencing market expansion and treatment accessibility worldwide. The market is demonstrating a capacity-constrained recovery, supported by expanding manufacturing capabilities, localized production strategies, and investments in resilient supply networks that are gradually restoring supply stability and supporting long-term growth.
Growing Adoption of Stem Cell-based Therapies for Companion Animals
The increasing prevalence of orthopedic disorders and chronic joint diseases in companion animals is driving the transition toward stem cell-based regenerative therapies as an alternative to conventional pain management and surgery. This trend is improving treatment outcomes while encouraging broader acceptance of regenerative medicine in routine veterinary practice. For example, VetStem Biopharma provides stem cell therapies for osteoarthritis and musculoskeletal conditions in companion animals.
Integration of Platelet-Rich Plasma into Advanced Veterinary Treatment Protocols
Growing demand for minimally invasive therapies is accelerating the integration of platelet-rich plasma (PRP) into veterinary orthopedic, sports medicine, and wound management protocols. Veterinary hospitals are increasingly incorporating PRP alongside rehabilitation programs to promote faster healing and reduce inflammation in performance and companion animals. This transition is expanding regenerative treatment options and strengthening personalized veterinary care.
The veterinary regenerative medicine market forecasts continued investment activity driven by rising demand for advanced biologic therapies and growing commercialization of stem cell and gene therapy platforms.
Key Investment and Funding Activities in Veterinary Regenerative Medicine Market, 2025–2026
Rejuvenate Bio
USD 6 million (Financing Round)
In June 2026, Rejuvenate Bio completed a financing round led by VCapital with participation from Merck Animal Health and other investors. The investment supports development of veterinary gene therapies and accompanies a strategic R&D collaboration with Merck Animal Health.
Gallant
USD 18 million (Series B financing)
In June 2025, Gallant raised a Series B round led by Digitalis Ventures. The funding will advance FDA conditional approval and commercialization of ready-to-use allogeneic stem cell therapies for companion animals.
Rising Prevalence of Musculoskeletal Disorders in Companion Animals and Growing Investment in Veterinary Biotechnology Drives Market
The increasing incidence of osteoarthritis, ligament injuries, and degenerative joint diseases in companion animals is driving demand for veterinary regenerative medicine therapies. Canine osteoarthritis remains the most common orthopedic disorder, with an annual prevalence of approximately 2.5% across more than 450,000 dogs, while the risk increases significantly with age, body weight, and neuter status. As pets live longer and obesity rates rise, veterinarians are increasingly adopting stem cell and platelet-rich plasma therapies to improve mobility, reduce pain, and delay invasive surgeries. This shift is expanding the use of regenerative treatments in specialty veterinary hospitals and rehabilitation centers, supporting broader market demand.
Increasing investments in veterinary biotechnology and regenerative medicine research are strengthening the development and commercialization of advanced biologic therapies. Pharmaceutical companies, biotechnology firms, and academic institutions are expanding research on stem cell, gene, and tissue engineering solutions for companion and livestock animals. This is improving product availability, encouraging innovation, and accelerating clinical adoption across veterinary practices. For example, companies such as Gallant are advancing allogeneic stem cell therapies for companion animals, supporting the expansion of regenerative treatment options worldwide.
High Cost of Regenerative Therapies and Limited Availability of Standardized Cell Banking Restrain Market Expansion
The high cost of stem cell therapies, platelet-rich plasma procedures, and regenerative biologics restrains the adoption of veterinary regenerative medicine, particularly in price-sensitive markets. Specialized laboratory processing, advanced equipment, and personalized treatment protocols increase the overall cost of therapy, making these treatments less accessible for many pet owners and livestock producers. As a result, the adoption of regenerative medicine remains concentrated in specialty veterinary hospitals and premium animal healthcare facilities, limiting broader market growth.
The limited availability of GMP-compliant cell processing facilities, veterinary biobanks, and specialized manufacturing infrastructure restrains the commercialization of veterinary regenerative medicine therapies. Many regenerative treatments require advanced cell isolation, expansion, cryopreservation, and quality control capabilities that are available only in a limited number of specialized laboratories. This increases production lead times, restricts product availability across regions, and slows the adoption of regenerative therapies in routine veterinary practice, particularly in emerging markets.
Expansion of Allogeneic Off-the-Shelf Cell Therapies and Integration of Regenerative Medicine into Equine Sports Medicine Offer Growth Opportunities to Market Players
The growing shift toward allogeneic, off-the-shelf stem cell therapies creates significant growth opportunities for veterinary biotechnology companies by enabling scalable manufacturing and broader clinical adoption. Unlike autologous therapies, these products reduce treatment time and simplify logistics for veterinary hospitals and clinics. As regulatory approvals increase, companies will be able to commercialize standardized regenerative therapies across larger geographic markets.
The increasing use of regenerative therapies in equine sports medicine is creating new growth opportunities for veterinary hospitals, specialty clinics, and regenerative medicine developers. Rising demand for faster recovery from tendon, ligament, and joint injuries is encouraging wider adoption of stem cell and platelet-rich plasma therapies in performance horses. As equine rehabilitation programs continue to expand, demand for advanced biologic treatments is expected to increase.
Limited Insurance Coverage and Difficulty in Scaling Personalized Regenerative Therapies Challenges Market Growth
The limited inclusion of regenerative therapies under companion animal insurance plans remains a significant challenge for market expansion. Many pet insurance providers classify stem cell and platelet-rich plasma treatments as experimental or offer only partial reimbursement, resulting in higher out-of-pocket expenses for pet owners. For example, Trupanion and several other insurers reimburse regenerative procedures only under specific policy conditions, limiting treatment uptake and slowing commercialization of advanced veterinary regenerative therapies.
Many veterinary regenerative medicine treatments are customized for individual animals, requiring patient-specific cell collection, processing, and treatment planning. This personalized approach limits manufacturing scalability, creates logistical complexities, and makes it difficult for companies to deliver standardized therapies across large veterinary networks.
Request Customizationto receive a tailored report.
The stem cells segment accounted for a share of 49.62% in 2025, owing to their ability to regenerate cartilage, tendon, and ligament tissues while providing long-lasting therapeutic benefits for chronic orthopedic diseases. Their expanding clinical evidence, availability for both autologous and allogeneic applications, and increasing commercialization further strengthen segment leadership.
The platelet-rich plasma segment is expected to grow at a CAGR of around 10.45% during the forecast period due to rapid preparation, minimal regulatory complexity, and increasing preference for same day treatment procedures. Growing adoption in postoperative recovery and sports medicine further accelerates demand across veterinary practices.
In 2025, the small animals segment is estimated to grow at a CAGR of 10.75% during the forecast period. This is due to increasing prevalence of degenerative diseases in companion animals is driving the adoption of regenerative therapies across veterinary practices. Rising expenditure on premium pet healthcare and growing acceptance of advanced biologic treatments among pet owners are further supporting segment growth.
The large animals segment is expected to grow at a CAGR of 11.27% during the forecast period, driven by increasing regenerative treatment for high value performance horses. Growing emphasis on reducing recovery time after tendon injuries and expanding equine rehabilitation programs further support market growth.
The orthopedics segment accounted for a share of 41.03% in 2025 due to the widespread use of regenerative therapies for osteoarthritis, ligament injuries, and cartilage repair. Rising clinical preference for biologic alternatives that improve mobility while reducing dependence on long term anti-inflammatory medications further supports segment dominance.
The trauma/wound care segment is expected to grow at a CAGR of 10.84% during the forecast period, driven by increasing incidence of traumatic injuries and postoperative wounds requiring advanced tissue repair. Growing adoption of regenerative therapies for managing non-healing wounds and accelerating soft tissue regeneration is further supporting segment growth.
The veterinary hospitals & clinics segment is projected to register a CAGR of 11.18% during the forecast period, as these facilities possess specialized diagnostic infrastructure, surgical expertise, and integrated rehabilitation services required for regenerative medicine procedures. Increasing referral cases further strengthens treatment volumes.
The veterinary research institutes expected to grow at a CAGR of 10.96% during the forecast timeframe, due to expanding translational research and increasing evaluation of novel regenerative therapies. Rising collaborations with biotechnology companies are accelerating the validation of advanced veterinary biologic treatments.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Advanced Veterinary Healthcare Infrastructure and High Companion Animal Healthcare Expenditure
The North America veterinary regenerative medicine market accounted for the largest regional share of 37.29% in 2025, driven by established veterinary specialty hospitals, high adoption of advanced biologic therapies, and increasing expenditure on companion animal healthcare. The region benefits from strong veterinary research capabilities, favorable commercialization of regenerative technologies, and growing awareness among pet owners regarding minimally invasive treatment options. According to the American Pet Products Association (APPA), US pet industry
The US veterinary regenerative medicine market was valued at USD 485.73 million in 2025, driven by increasing adoption of stem cell, platelet-rich plasma (PRP), and regenerative biologic therapies for companion animals and equine healthcare. Veterinary specialty hospitals and referral centers are expanding regenerative treatment offerings to manage orthopedic disorders, chronic pain, and sports-related injuries. expenditure reached USD 157 billion in 2025, reflecting continued investment in advanced veterinary care and supporting demand for regenerative therapies.
The veterinary regenerative medicine market in Canada was valued at USD 70.66 million in 2025, propelled by rising pet ownership, increasing awareness of advanced veterinary treatment options, and growing demand for minimally invasive therapies. Veterinary clinics are progressively incorporating regenerative medicine into orthopedic and rehabilitation services to improve clinical outcomes for companion animals.
Asia Pacific: Fastest Growth Driven by Rising Companion Animal Ownership and Expanding Veterinary Specialty Care
The Asia Pacific veterinary regenerative medicine market is expected to grow at a CAGR of 11.70% during the forecast period, showcasing the fastest regional growth. Growth is supported by rising companion animal ownership, increasing veterinary healthcare expenditure, and expanding availability of specialty veterinary hospitals. Countries across the region are investing in advanced animal healthcare services, while growing awareness of regenerative therapies is accelerating clinical adoption.
The China veterinary regenerative medicine market was valued at USD 83.79 million in 2025, supported by rapid growth in companion animal ownership, expanding veterinary hospital networks, and increasing investment in animal biotechnology. Government support for biotechnology innovation and rising demand for advanced treatment options is encouraging the adoption of stem cell and regenerative biologic therapies. The country's growing veterinary infrastructure continues to strengthen market expansion.
The India veterinary regenerative medicine market was valued at USD 42.86 million in 2025, fueled by increasing pet humanization, expanding multispecialty veterinary hospitals, and rising awareness of advanced regenerative treatment options. Growing investment in companion animal healthcare and improving access to specialized veterinary services are supporting the adoption of stem cell and platelet-rich plasma therapies.
The Japan veterinary regenerative medicine market was valued at USD 49.45 million in 2025, supported by advanced veterinary research ecosystem and growing demand for treatments addressing age related mobility disorders. According to the Japan Pet Food Association, Japan had approximately 15.9 million pet dogs and cats in 2025, highlighting a large addressable population for advanced veterinary treatments.
Unlock Regional Insightsto access country-level data, & regional trends.
The veterinary regenerative medicine market competitive landscape is moderately consolidated, with competition driven by specialized biotechnology companies, regenerative medicine developers, and animal health firms expanding advanced biologic therapies for companion animals and equine care. Market participants compete through product innovation, clinical research, strategic partnerships, and regulatory advancements to strengthen their commercial presence. The veterinary regenerative medicine market ecosystem is shaped by increasing investment in regenerative biotechnology, expanding veterinary specialty care, and growing demand for minimally invasive treatments.
February 2026: Gallant entered into a fulfillment agreement with MWI Animal Health (Cencora) to establish the cold chain for veterinary medicine, supporting commercial distribution of its anticipated FDA approved off-the-shelf stem cell therapy to veterinary clinics.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com